Alpha Paradigm Partners’s Novavax NVAX Stock Holding History

Alpha Paradigm Partners’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-737	Closed	-$13K	–	570
2022 Q3	$13K	Hold	737	–	–	0.01%	439
2022 Q2	$38K	Hold	737	–	–	0.02%	452
2022 Q1	$54K	Buy	737 +730	+10,429%	+$65.1K	0.02%	471
2021 Q4	$1K	Hold	7	–	–	﹤0.01%	525
2021 Q3	$1K	Sell	7 -606	-99%	-$134K	﹤0.01%	522
2021 Q2	$130K	Sell	613 -3,275	-84%	-$600K	0.05%	411
2021 Q1	$705K	Hold	3,888	–	–	0.28%	112
2020 Q4	$434K	Buy	+3,888	New	+$413K	0.15%	167

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

HIG

Herr Investment Group Austin, Texas $1.5B AUM 29.27% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Alpha Paradigm Partners's NVAX Position: Q4 2022 in Review

Alpha Paradigm Partners sold out of Novavax (NVAX) in Q4 2022, closing a stake of 737 shares — an estimated $13K sold.

Alpha Paradigm Partners first reported a position in NVAX in Q4 2020 and held it in 8 quarters. The position peaked at $705K in Q1 2021. 252 funds tracked by Wall St. Rank hold NVAX as of Q4 2022.

Alpha Paradigm Partners reported no remaining Novavax position as of Q4 2022 after selling out during the quarter.
Alpha Paradigm Partners sold 737 Novavax shares in Q4 2022, an estimated $13K.
Alpha Paradigm Partners first reported a position in Novavax in Q4 2020 and held it in 8 quarters.
Alpha Paradigm Partners's Novavax position peaked at $705K in Q1 2021.
252 funds tracked by Wall St. Rank held Novavax as of Q4 2022.

Based on Alpha Paradigm Partners's 13F filing for Q4 2022, filed 13 Feb 2023.